Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment
Kelly L. Singel, Tiffany R. Emmons, ANM Nazmul H. Khan, Paul C. Mayor, Shichen Shen, Jerry T. Wong, Kayla Morrell, Kevin H. Eng, Jaron Mark, Richard B. Bankert, Junko Matsuzaki, Richard C. Koya, Anna M. Blom, Kenneth R. McLeish, Jun Qu, Sanjay Ram, Kirsten B. Moysich, Scott I. Abrams, Kunle Odunsi, Emese Zsiros, Brahm H. Segal
Kelly L. Singel, Tiffany R. Emmons, ANM Nazmul H. Khan, Paul C. Mayor, Shichen Shen, Jerry T. Wong, Kayla Morrell, Kevin H. Eng, Jaron Mark, Richard B. Bankert, Junko Matsuzaki, Richard C. Koya, Anna M. Blom, Kenneth R. McLeish, Jun Qu, Sanjay Ram, Kirsten B. Moysich, Scott I. Abrams, Kunle Odunsi, Emese Zsiros, Brahm H. Segal
View: Text | PDF
Research Article Immunology Oncology

Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment

  • Text
  • PDF
Abstract

Epithelial ovarian cancer (EOC) often presents with metastases and ascites. Granulocytic myeloid–derived suppressor cells are an immature population that impairs antitumor immunity. Since suppressive granulocytes in the ascites of patients with newly diagnosed EOC were morphologically mature, we hypothesized that PMN were rendered suppressive in the tumor microenvironment (TME). Circulating PMN from patients were not suppressive but acquired a suppressor phenotype (defined as ≥1 log10 reduction of anti-CD3/CD28–stimulated T cell proliferation) after ascites supernatant exposure. Ascites supernatants (20 of 31 supernatants) recapitulated the suppressor phenotype in PMN from healthy donors. T cell proliferation was restored with ascites removal and restimulation. PMN suppressors also inhibited T cell activation and cytokine production. PMN suppressors completely suppressed proliferation in naive, central memory, and effector memory T cells and in engineered tumor antigen–specific cytotoxic T lymphocytes, while antigen-specific cell lysis was unaffected. Inhibition of complement C3 activation and PMN effector functions, including CR3 signaling, protein synthesis, and vesicular trafficking, abrogated the PMN suppressor phenotype. Moreover, malignant effusions from patients with various metastatic cancers also induced the C3-dependent PMN suppressor phenotype. These results point to PMN impairing T cell expansion and activation in the TME and the potential for complement inhibition to abrogate this barrier to antitumor immunity.

Authors

Kelly L. Singel, Tiffany R. Emmons, ANM Nazmul H. Khan, Paul C. Mayor, Shichen Shen, Jerry T. Wong, Kayla Morrell, Kevin H. Eng, Jaron Mark, Richard B. Bankert, Junko Matsuzaki, Richard C. Koya, Anna M. Blom, Kenneth R. McLeish, Jun Qu, Sanjay Ram, Kirsten B. Moysich, Scott I. Abrams, Kunle Odunsi, Emese Zsiros, Brahm H. Segal

×

Figure 4

PMN suppressor phenotype requires SNARE transport and Ca2+ mobilization, and it is abrogated by desensitization with fMLF.

Options: View larger image (or click on image) Download as PowerPoint
PMN suppressor phenotype requires SNARE transport and Ca2+ mobilization,...
(A–F) PMN were treated with media, fMLF (100 nM), ASC (n = 3), or heat-inactivated ASC (HI-ASC; n = 3) and assessed for markers of membrane fusion with primary (CD63), secondary and tertiary (CD66b) granules, and secretory vesicles (CD35) at 0, 30, and 60 minutes. PMN were gated on CD45+CD15+. (A, C, and E) The MFI overlays are representative; unstimulated PMN in media, gray solid; fMLF, black dashed line; ASC, green line; HI-ASC, purple line. (B, D, and F) MFI quantification. (G–I) T cells (CD3+) and PMN were used in autologous coculture at 1:1. PMN and/or ascites supernatants (ASC; 50% final well volume) were added to anti-CD3/CD28–stimulated T cells. After 72 hours of coculture, T cell proliferation was measured by [3H] thymidine incorporation (16–18 hours). (G) Pretreatment with brefeldin-A (BFA; 1–10 μg/ml) or ER export inhibitor 1 (Exo1; 20–75 μM) abrogated the suppressor phenotype, indicating a requirement for exocytosis (n = 3). (H) PMN pretreated with TAT-SNAP23 (0.6 μg) or TAT-SYN4 (0.6 μg) abrogated the PMN suppressor phenotype. TAT-GST (0.6 μg) used as a specificity control had no effect (n = 3). (I) PMN pretreated with fMLF (100 nM), thapsigargin (THG, 1 μM), or diphenyleneiodonium (DPI, 1 μM) abrogated the PMN suppressor phenotype (n = 7). Symbols represent individual samples (n), and bars represent ± SEM. Statistical comparisons were by ANOVA with Tukey post hoc test (**P < 0.01; ***P < 0.001).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts